This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. By way of ...
Patients with CML, unlike patients with acute lymphoblastic leukemia, are likely to have a longer life expectancy with and ...
Autologous reconstitution is the recovery of autologous hematopoietic function after failure of an allogeneic graft to establish sustained hematopoiesis either with or without preceding donor ...
Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a ...
Targeted Therapy and Evolving Research: Where Are We Winning and Losing in Chronic Myeloid Leukemia?
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Mauro: I have been ...
In this video, Christine McMahon, MD, discusses the results of the phase 3 ASC4FIRST study, pertaining to chronic myelogenous leukemia, presented at ASCO Annual Meeting. McMahon, an assistant ...
The FDA approves generic dasatinib tablets, enhancing access and affordability for treating chronic myeloid leukemia and ...
A retrospective cohort was constructed from the OptumLabs Data Warehouse using claims from 2000 to 2016. Eligible patients had ≥ 2 CML claims and were enrolled continuously for ≥ 6 months before ...
CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...
A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback